Immuron (NASDAQ:IMRN) Stock Crosses Below Fifty Day Moving Average – Should You Sell?

Posted by Alphonse Anthony on Jul 31st, 2026

Immuron (NASDAQ:IMRN – Get Free Report)’s share price passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $1.16 and traded as low as $1.0301. Immuron shares last traded at $1.11, with a volume of 21,507 shares traded.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Immuron in a research note on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

Get Our Latest Stock Analysis on Immuron

Immuron Price Performance

The firm has a 50-day simple moving average of $1.16 and a two-hundred day simple moving average of $0.96.

Hedge Funds Weigh In On Immuron

An institutional investor recently bought a new position in Immuron stock. Citadel Advisors LLC purchased a new position in shares of Immuron (NASDAQ:IMRN – Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 19,562 shares of the company’s stock, valued at approximately $37,000. Citadel Advisors LLC owned about 0.29% of Immuron as of its most recent SEC filing. Hedge funds and other institutional investors own 0.12% of the company’s stock.

About Immuron

(Get Free Report)

Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections.